ATE452204T1 - Screening-methoden unter verwendung eines strukturmodells von fih - Google Patents

Screening-methoden unter verwendung eines strukturmodells von fih

Info

Publication number
ATE452204T1
ATE452204T1 AT03758318T AT03758318T ATE452204T1 AT E452204 T1 ATE452204 T1 AT E452204T1 AT 03758318 T AT03758318 T AT 03758318T AT 03758318 T AT03758318 T AT 03758318T AT E452204 T1 ATE452204 T1 AT E452204T1
Authority
AT
Austria
Prior art keywords
fih
structural model
structural
screening methods
chemical entity
Prior art date
Application number
AT03758318T
Other languages
English (en)
Inventor
Peter John Ratcliffe
Christopher William Pugh
Christopher Joseph Schofield
Kirsty Sarah Hewitson
Jonathan Mark Elkins
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224102A external-priority patent/GB0224102D0/en
Priority claimed from GB0226598A external-priority patent/GB0226598D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE452204T1 publication Critical patent/ATE452204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Evolutionary Biology (AREA)
  • Cardiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Computing Systems (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03758318T 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih ATE452204T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224102A GB0224102D0 (en) 2002-10-16 2002-10-16 Inhibitors
GB0226598A GB0226598D0 (en) 2002-11-14 2002-11-14 Chemical inhibitors
PCT/GB2003/004492 WO2004035812A2 (en) 2002-10-16 2003-10-16 Asparaginyl hydroxylases and modulators thereof

Publications (1)

Publication Number Publication Date
ATE452204T1 true ATE452204T1 (de) 2010-01-15

Family

ID=32109245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03758318T ATE452204T1 (de) 2002-10-16 2003-10-16 Screening-methoden unter verwendung eines strukturmodells von fih

Country Status (11)

Country Link
US (1) US7778779B2 (de)
EP (2) EP1554394B1 (de)
JP (1) JP4465276B2 (de)
AT (1) ATE452204T1 (de)
AU (1) AU2003274330B2 (de)
CA (1) CA2502541A1 (de)
DE (1) DE60330587D1 (de)
ES (1) ES2337043T3 (de)
MX (1) MXPA05004033A (de)
PL (1) PL376770A1 (de)
WO (1) WO2004035812A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638295B2 (en) 2004-03-26 2009-12-29 Isis Innovation Limited Assays for identifying modulators of the hydroxylation of ankyrin repeat proteins by 2-oxoglutarate dependent oxygenase and methods of using the same
MX2007000428A (es) 2004-07-15 2008-03-05 Amr Technology Inc Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
GB0519605D0 (en) 2005-09-26 2005-11-02 Isis Innovation Assay
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
JP5113838B2 (ja) 2006-06-26 2013-01-09 アケビア セラピューティックス， インコーポレイテッド プロリルヒドロキシラーゼ阻害剤および使用方法
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AU2009328502B2 (en) * 2008-12-19 2015-02-05 Centre National De La Recherche Scientifique, Direction De La Politique Industrielle Polypeptide fragments comprising endonuclease activity and their use
CN102638982B (zh) * 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
DK2429296T3 (en) * 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
EP2496236B1 (de) 2009-11-06 2013-05-01 Aerpio Therapeutics Inc. Prolylhydroxylasehemmer
NZ767139A (en) 2009-12-04 2022-08-26 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
US8865748B2 (en) 2011-06-06 2014-10-21 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (de) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP3345596B1 (de) * 2012-09-21 2021-01-20 Rhode Island Hospital Beta-hydrolase-hemmer zur behandlung von krebs
RS65341B1 (sr) 2013-06-13 2024-04-30 Akebia Therapeutics Inc Kompozicije i postupci za lečenje anemije
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
US10312653B2 (en) 2015-05-06 2019-06-04 Milwaukee Electric Tool Corporation Hydraulic tool
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 化合物および組成物ならびにそれらの使用
BR112019001439A8 (pt) 2016-07-29 2019-11-12 Pgi Drug Discovery Llc compostos e composições e usos dos mesmos
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
US10815249B2 (en) 2018-02-16 2020-10-27 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
AR114886A1 (es) 2018-05-09 2020-10-28 Akebia Therapeutics Inc Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
MX2022012833A (es) 2020-04-14 2022-11-07 Sunovion Pharmaceuticals Inc (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001251467A1 (en) 2000-05-17 2001-12-03 Princeton University Methods of making models, methods of using models of murg, compounds that bind, inhibit or stimulate muret proteins, and therapeutic compositions thereof
GB0017323D0 (en) 2000-07-15 2000-08-30 Univ St Andrews Enzyme
DK1327143T3 (da) 2000-09-22 2007-07-02 Wyeth Corp Krystalstruktur af BACE og anvendelse deraf
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
AUPR773801A0 (en) * 2001-09-18 2001-10-11 Adelaide Research & Innovation Pty Ltd Asparagine hydroxylation of the cad domain of a hif protein

Also Published As

Publication number Publication date
ES2337043T3 (es) 2010-04-20
CA2502541A1 (en) 2004-04-29
US20070048728A1 (en) 2007-03-01
WO2004035812A3 (en) 2004-08-19
DE60330587D1 (de) 2010-01-28
JP4465276B2 (ja) 2010-05-19
EP1554394B1 (de) 2009-12-16
US7778779B2 (en) 2010-08-17
AU2003274330A1 (en) 2004-05-04
EP2156830A1 (de) 2010-02-24
EP1554394A2 (de) 2005-07-20
PL376770A1 (pl) 2006-01-09
JP2006504415A (ja) 2006-02-09
AU2003274330B2 (en) 2009-06-04
MXPA05004033A (es) 2005-06-08
WO2004035812A2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
ATE452204T1 (de) Screening-methoden unter verwendung eines strukturmodells von fih
Livingstone et al. The prediction of hypolimnetic oxygen profiles: a plea for a deductive approach
Wisshak et al. Ocean acidification accelerates reef bioerosion
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
SE0201812D0 (sv) Dynamic on-line optimization of production processes
DE10345743A1 (de) Verfahren und Vorrichtung zum Bestimmen von Position und Orientierung einer Bildempfangseinrichtung
DK0944731T3 (da) Enzymsensor
DE60334365D1 (de) Leistungsverbesserung einer analytenüberwachungsvorrichtung
EA200501193A1 (ru) Улучшенный способ и система для выявления и/или прогнозирования биологических аномалий, например церебральных нарушений
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
ATE496141T1 (de) Verfahren und system zum analysieren von reaktionen unter verwendung eines informationssystems
DE69634782D1 (de) Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12
ATE507512T1 (de) Verfahren, computerprogramm mit programmcode- mitteln und computerprogramm-produkt zur analyse von einflussgrössen auf einen brennvorgang in einer brennkammer unter verwendung eines trainierbaren, statistischen modells
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE279769T1 (de) Vorrichtung und verfahren zum analysieren eines audiosignals hinsichtlich von rhythmusinformationen
ATE459077T1 (de) Verfahren und vorrichtung zur bestimmung der aufzeichnungsparameter von optischen platten
ATE532073T1 (de) Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
ATE221657T1 (de) Entstörung durch rheumafaktoren
DE69928250D1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
DE602006007734D1 (de) Verfahren und system zur echtzeitanalyse von biosensordaten
DE3850346D1 (de) Verfahren zur Selbstdurchführung von Enzymkinetik.
ATE527596T1 (de) Erhalten von konfigurationsdaten für ein datenverarbeitungsgerät
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
WO2002072551A3 (en) A non-traumatic model for neurogenic pain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties